Exchange: NYSE·Updated 07:59 PM EST
JNJ logo

JNJ Johnson & Johnson

$270.47
$3.33
(1.25%)
Today
Closed $270.47
$0.00
(0.00%)
After Hours
EarningsJan 26
Mkt Cap$651.11B
Vol11.93M

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
56

Bullish Sentiment

How do you feel about JNJ?

Gfywoody
$JNJ I really hope you guys do a one for one share purchase of Sellas. I love dividends.
10
Suite510
$JNJ $SPX Oh look more trouble 😈 🙈🤣 NEW YORK, Nov. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson ("J&J" or the "Company") (NYSE: JNJ). no wonder it’s tanking
2
TitanMoonofSaturn
$JNJ $AVR J&J has spent roughly $30B building a heart business and still doesn't have a valve. Abiomed: ~$16.6B (2022) Shockwave: ~$13.1B (2024) Laminar: $400M upfront (2023) Atraverse: announced this year And Q3 wasn't pretty. MedTech grew 2.5%, below their own targets. Cardio slowed to 4.3% after running double digits. Abiomed actually shrank 2.3%. Schmid: "we can do better, and we absolutely will." That's heart recovery, circulation, rhythm and LAA covered. No TAVR. They're the only major cardio player sitting out one of the biggest device markets in cardiology. Everyone else is picking a balloon-expandable bet. BSX put $1.5B into MiRus. Medtronic took a stake in Anteris. Abbott is building its own, still at 11 patients in feasibility. Wolk on the call: "We always are on the lookout for strategic drivers that could complement our business." Not many independent BE platforms with real data left, let alone differentiated like duravr! This is masqueraded on purpose imo
7
UncleSteven
IMO, it's too late to swap AI and tech into $JNJ $PG $KO whatever defensive stocks. You're just locking in your losses. You should be moving in the other direction. Just my opinion. Don't do what I say. I don't know anything. I'm down nearly one entry-level Ferrari from my ATH. Listen to Tom Lee or Nancy.
1
1
Suite510
$JNJ $SPX Lawyers for shareholders say they are preparing for trial J&J estimated potential damages exceed $10 billion in Supreme Court filing. Lanier represented women who sued J&J over talc products ooops 😅
1
1
abubnic
$JNJ #ESMO Johnson & Johnson advances the next generation of solid tumor therapies with new data at ESMO 2026. First readout following acquisition of the RIPTAC™ platform shows promising anti-tumor activity with JNJ-6143, a novel oral investigational molecule, in difficult-to-treat prostate cancer. It offers a completely new way of thinking about cancer therapy.
4
Gfywoody
$JNJ Reddit Sellas followers encourage an all stock exchange of J&J to the tune of 40billy.
3
AlertsAndNews
$JNJ FDA approval Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer "Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent"
3
DERICKTRADE
🟢 $JNJ 11/27/26 $282.5 CALL @ $0.53 Swing Setup 📈 Manage Your Risk (MYR). Wait for confirmation and follow the entry plan.
1
openclassaction2
$JNJ: no talc claim portal exists. With MDL 2738 still in mediation and no global deal, ovarian cancer cases move only as individual suits after attorney review. J&J denies the allegations. Open Class Actions.
2
Baozun13
$JNJ why did this suddenly double is there any fundamental change or is this just a sign of the times -
2
openclassaction2
$JNJ: a leadership fight is still shaping the talc MDL. On May 26 the court denied Beasley Allen a stay of its disqualification in MDL 2738. Mediation continues, no global settlement, nothing to claim. Open Class Actions.
2
chursinow62
$JNJ Rybrevant cancer treatment is a second drug rolled out today signaling reduction in head and neck plus the prostate cancer breakthrough 🚀🚀🚀🚀🚀$300 this week
2
peloswing
$JNJ may be down over -2% today, but netflow is showing call selling NOT put buying! GEX Heatmap is showing the King Node at $270 for TOMORROW. $JNJ may see the supporting trendline and is likely to bounce, but even is that support level of ~$260 is broken, the 50WMA and VPoC is an additional level of support at $240-243!
1
openclassaction2
$JNJ 68,029 talc cases were pending in mdl 2738 as of june 1, per open class actions. lawsuit stage, no nationwide settlement, nothing to claim. seems like legacy bills outlast growth stories
1
theoptionsplug
So will $JNJ just forever keep going up?! Looking to see a break under $282 for put entry towards ~$275 then $262.45
1
GettnFibbywIT
$JNJ $XLV $IHE JNJ - Weekly Chart The "bull flag" pattern is often ( though not always) a continuation formation. A commonly used measured-move technique among discretionary traders is to add the length of the flagpole to the breakout level of the flag. Applying that framework here suggests a "potential" longer-term upside objective in the $340 -$345 ish range, based on an approximately 100-point flagpole advance added to the $240 breakout area. Measured-move targets should always be viewed as guideline objectives rather than forecasts and should be approached with appropriate risk management. However, JNJ's successful retest and acceptance of former resistance levels near $263 and $270, combined with constructive weekly momentum, reinforces confidence that the broader uptrend remains intact and that buyers continue to defend higher price levels.
1
theoptionsplug
$JNJ has once again struggled and rejected the $280 resistance area A break of $278.75 is the put trigger targeting $275.25 then $271.35
1
Invescent
$JNJ | Johnson & Johnson announces significant improvements in psoriatic arthritis disease outcomes from its Phase 3 clinical study.
1
Rayvio_News_Filter
$JNJ · $HALO 🏥 The U.S. FDA granted accelerated approval to Johnson & Johnson's RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), co-formulated with Halozyme's ENHANZE, as a single agent for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. Curated for market relevance
1

Advertisement|Remove ads.